logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age : A cost-consequence model.

    Article - En anglais

    A method was developed for modeling the costs and consequences of treating varicella zoster viral infections to clinical data generated in a pivotal phase III clinical trial of valaciclovir versus acyclovir for the treatment of acute herpes zoster in immunocompetent patients over 50 years of age.

    Direct medical costs and indirect costs (productivity losses) were modeled using unit costs applicable in the United States.

    Compared with acyclovir, valaciclovir reduced average direct medical costs per patient by 17% ($60.01) and indirect costs by an average of 25% ($46.54).

    Median duration of pain was reduced by 13 days for valaciclovir compared with acyclovir in the intent-to-treat population or by 19 days in patients with pain after rash healing.

    The cost variables described in the model (drug costs, cost of treating long-term pain, physician visits, hospitalization, treatment of severe ocular involvement, productivity losses) were tested by sensitivity analysis.

    Total costs associated with valaciclovir treatment remained lower than those with acyclovir over the range of the analysis.

    Mots-clés Pascal : Valaciclovir, Complication, Coût global, Aciclovir, Etude comparative, Virose, Infection, Herpès, Immunocompétence, Homme, Chimiothérapie, Traitement, Adulte, Analyse coût efficacité, Economie santé, Antiviral, Modèle, Nucléoside acyclique, Purine nucléoside, Virus varicelle, Alphaherpesvirinae, Herpesviridae, Virus

    Mots-clés Pascal anglais : Valaciclovir, Complication, Life cycle cost, Aciclovir, Comparative study, Viral disease, Infection, Herpes, Immunocompetence, Human, Chemotherapy, Treatment, Adult, Cost efficiency analysis, Health economy, Antiviral, Models, Acyclic nucleoside, Purine nucleoside, Varicella zoster virus, Alphaherpesvirinae, Herpesviridae, Virus

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0268971

    Code Inist : 002B02S05. Création : 15/07/1997.